Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acyla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endokrynologia Polska 2022-01
Hauptverfasser: Nowak, Mariusz, Nowak, Wojciech, Grzeszczak, Władysław
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Endokrynologia Polska
container_volume
creator Nowak, Mariusz
Nowak, Wojciech
Grzeszczak, Władysław
description The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acylation technology allows it to bind to albumin, thus making it possible to dose the drug once a week. This review summarizes the key characteristics and pharmacokinetics of tirzepatide. The authors present the results of a phase 1, 2, and 3 clinical trial on the effects of tirzepatide on glycaemic and lipid control and the beneficial effects on body weight in a dose-dependent manner in patients with type 2 diabetes mellitus (T2DM). Tirzepatide has the ability to reduce glycaemic levels, improve insulin sensitivity, reduce body weight, and improve lipid metabolism, which is critically important in T2DM. Tirzepatide administered by weekly subcutaneous injections appears to be a promising drug for the treatment of T2DM as well as cardiometabolic disorders. The mechanism of action and safety profile of tirzepatide potentially fills important gaps in the current treatment of T2DM.
doi_str_mv 10.5603/EP.a2022.0029
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_5603_EP_a2022_0029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35593668</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-2b5d34c12463d168a61580637a2942404b904067e3f14f02468f69531dbf427c3</originalsourceid><addsrcrecordid>eNo9kM1OwkAURidGIwRZujX3BQp35k6HdmkIIgmJXWDirpm2U5iE_mQ6SPAlfGULqKu7-M49i8PYI8dJqJCmi2SiBQoxQRTxDRsKEcdBRKhu2RCloICj_BiwcdfZDAUpiRGpezagMIxJqWjIvjfWfZlWe1sYCEBDcdB7WK6S6XKdBBycyU3rGwd629S28xemNkfQdf9idWa8zaFwhy0crd9B23jTL72jMl5nzb5fde7tp_UnsDX4nQHvjPZVj0FTgj-1BgRcVaZ7YHel3ndm_HtH7P1lsZm_Buu35Wr-vA5yIuEDkYUFyZwLqajgKtKKhxEqmmkRSyFRZjFKVDNDJZcl9lhUqjgkXmSlFLOcRiy4enPXdJ0zZdo6W2l3Sjmm57bpIkkvbdNz255_uvLtIatM8U__laQf5aZzmQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nowak, Mariusz ; Nowak, Wojciech ; Grzeszczak, Władysław</creator><creatorcontrib>Nowak, Mariusz ; Nowak, Wojciech ; Grzeszczak, Władysław</creatorcontrib><description>The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acylation technology allows it to bind to albumin, thus making it possible to dose the drug once a week. This review summarizes the key characteristics and pharmacokinetics of tirzepatide. The authors present the results of a phase 1, 2, and 3 clinical trial on the effects of tirzepatide on glycaemic and lipid control and the beneficial effects on body weight in a dose-dependent manner in patients with type 2 diabetes mellitus (T2DM). Tirzepatide has the ability to reduce glycaemic levels, improve insulin sensitivity, reduce body weight, and improve lipid metabolism, which is critically important in T2DM. Tirzepatide administered by weekly subcutaneous injections appears to be a promising drug for the treatment of T2DM as well as cardiometabolic disorders. The mechanism of action and safety profile of tirzepatide potentially fills important gaps in the current treatment of T2DM.</description><identifier>ISSN: 0423-104X</identifier><identifier>EISSN: 2299-8306</identifier><identifier>DOI: 10.5603/EP.a2022.0029</identifier><identifier>PMID: 35593668</identifier><language>eng</language><publisher>Poland</publisher><ispartof>Endokrynologia Polska, 2022-01</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c332t-2b5d34c12463d168a61580637a2942404b904067e3f14f02468f69531dbf427c3</citedby><orcidid>0000-0003-1947-3783 ; 0000-0003-1754-9959</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35593668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nowak, Mariusz</creatorcontrib><creatorcontrib>Nowak, Wojciech</creatorcontrib><creatorcontrib>Grzeszczak, Władysław</creatorcontrib><title>Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes</title><title>Endokrynologia Polska</title><addtitle>Endokrynol Pol</addtitle><description>The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acylation technology allows it to bind to albumin, thus making it possible to dose the drug once a week. This review summarizes the key characteristics and pharmacokinetics of tirzepatide. The authors present the results of a phase 1, 2, and 3 clinical trial on the effects of tirzepatide on glycaemic and lipid control and the beneficial effects on body weight in a dose-dependent manner in patients with type 2 diabetes mellitus (T2DM). Tirzepatide has the ability to reduce glycaemic levels, improve insulin sensitivity, reduce body weight, and improve lipid metabolism, which is critically important in T2DM. Tirzepatide administered by weekly subcutaneous injections appears to be a promising drug for the treatment of T2DM as well as cardiometabolic disorders. The mechanism of action and safety profile of tirzepatide potentially fills important gaps in the current treatment of T2DM.</description><issn>0423-104X</issn><issn>2299-8306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNo9kM1OwkAURidGIwRZujX3BQp35k6HdmkIIgmJXWDirpm2U5iE_mQ6SPAlfGULqKu7-M49i8PYI8dJqJCmi2SiBQoxQRTxDRsKEcdBRKhu2RCloICj_BiwcdfZDAUpiRGpezagMIxJqWjIvjfWfZlWe1sYCEBDcdB7WK6S6XKdBBycyU3rGwd629S28xemNkfQdf9idWa8zaFwhy0crd9B23jTL72jMl5nzb5fde7tp_UnsDX4nQHvjPZVj0FTgj-1BgRcVaZ7YHel3ndm_HtH7P1lsZm_Buu35Wr-vA5yIuEDkYUFyZwLqajgKtKKhxEqmmkRSyFRZjFKVDNDJZcl9lhUqjgkXmSlFLOcRiy4enPXdJ0zZdo6W2l3Sjmm57bpIkkvbdNz255_uvLtIatM8U__laQf5aZzmQ</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Nowak, Mariusz</creator><creator>Nowak, Wojciech</creator><creator>Grzeszczak, Władysław</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-1947-3783</orcidid><orcidid>https://orcid.org/0000-0003-1754-9959</orcidid></search><sort><creationdate>20220101</creationdate><title>Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes</title><author>Nowak, Mariusz ; Nowak, Wojciech ; Grzeszczak, Władysław</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-2b5d34c12463d168a61580637a2942404b904067e3f14f02468f69531dbf427c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nowak, Mariusz</creatorcontrib><creatorcontrib>Nowak, Wojciech</creatorcontrib><creatorcontrib>Grzeszczak, Władysław</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Endokrynologia Polska</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nowak, Mariusz</au><au>Nowak, Wojciech</au><au>Grzeszczak, Władysław</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes</atitle><jtitle>Endokrynologia Polska</jtitle><addtitle>Endokrynol Pol</addtitle><date>2022-01-01</date><risdate>2022</risdate><issn>0423-104X</issn><eissn>2299-8306</eissn><abstract>The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acylation technology allows it to bind to albumin, thus making it possible to dose the drug once a week. This review summarizes the key characteristics and pharmacokinetics of tirzepatide. The authors present the results of a phase 1, 2, and 3 clinical trial on the effects of tirzepatide on glycaemic and lipid control and the beneficial effects on body weight in a dose-dependent manner in patients with type 2 diabetes mellitus (T2DM). Tirzepatide has the ability to reduce glycaemic levels, improve insulin sensitivity, reduce body weight, and improve lipid metabolism, which is critically important in T2DM. Tirzepatide administered by weekly subcutaneous injections appears to be a promising drug for the treatment of T2DM as well as cardiometabolic disorders. The mechanism of action and safety profile of tirzepatide potentially fills important gaps in the current treatment of T2DM.</abstract><cop>Poland</cop><pmid>35593668</pmid><doi>10.5603/EP.a2022.0029</doi><orcidid>https://orcid.org/0000-0003-1947-3783</orcidid><orcidid>https://orcid.org/0000-0003-1754-9959</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0423-104X
ispartof Endokrynologia Polska, 2022-01
issn 0423-104X
2299-8306
language eng
recordid cdi_crossref_primary_10_5603_EP_a2022_0029
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals
title Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A42%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tirzepatide%20-%20a%20dual%20GIP/GLP-1%20receptor%20agonist%20-%20a%20new%20antidiabetic%20drug%20with%20potential%20metabolic%20activity%20in%20the%20treatment%20of%20type%202%20diabetes&rft.jtitle=Endokrynologia%20Polska&rft.au=Nowak,%20Mariusz&rft.date=2022-01-01&rft.issn=0423-104X&rft.eissn=2299-8306&rft_id=info:doi/10.5603/EP.a2022.0029&rft_dat=%3Cpubmed_cross%3E35593668%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35593668&rfr_iscdi=true